KDR and neoplasm: Studies have shown that, first of all, antiangiogenic small molecule tyrosine kinase inhibitor can target VEGFR, normalize tumor vessels, thus improve tumor cell hypoxia and promote effective T cell infiltration into tumor tissue (17).